Earnings summaries and quarterly performance for OPPENHEIMER HOLDINGS.
Executive leadership at OPPENHEIMER HOLDINGS.
Board of directors at OPPENHEIMER HOLDINGS.
AG
Albert G. Lowenthal
Detailed
Chair of the Board
EB
Evan Behrens
Detailed
Director
PM
Paul M. Friedman
Detailed
Lead Independent Director
RL
R. Lawrence Roth
Detailed
Director
SJ
Stacy J. Kanter
Detailed
Director
SE
Suzanne E. Spaulding
Detailed
Director
TA
Teresa A. Glasser
Detailed
Director
TM
Timothy M. Dwyer
Detailed
Director
Research analysts covering OPPENHEIMER HOLDINGS.
Recent press releases and 8-K filings for OPY.
Oppenheimer Holdings Inc. Reports Record Q4 and Full Year 2025 Results
OPY
Earnings
Dividends
Share Buyback
- Oppenheimer Holdings Inc. reported record high revenue of $472.6 million and basic earnings per share of $7.08 for Q4 2025, and $1.6 billion in revenue and basic earnings per share of $14.13 for the full year 2025.
- Net income attributable to Oppenheimer Holdings Inc. saw significant growth, reaching $74.36 million in Q4 2025 (up 593.1% year-over-year) and $148.4 million for the full year 2025 (up 107.4% year-over-year).
- The company's financial position strengthened, with record high stockholders' equity of $983.8 million, book value per share of $93.81, and tangible book value per share of $76.78 as of December 31, 2025.
- Shareholder returns included a $1.00 per share special dividend declared for January 2026 and the repurchase of 46,292 shares in 2025 at an average price of $64.36 per share.
- Growth was supported by improved performance in Wealth Management, with record high Assets Under Management (AUM) of $55.2 billion and client assets under administration of $143.3 billion as of December 31, 2025, and increased investment banking activity.
4 days ago
Oppenheimer Holdings Inc. Reports Fourth Quarter and Full Year 2025 Earnings
OPY
Earnings
Dividends
Share Buyback
- For the fourth quarter of 2025, Oppenheimer Holdings Inc. reported net income of $74.4 million and basic earnings per share of $7.08, with revenue reaching $472.6 million. For the full year ended December 31, 2025, net income was $148.4 million and basic EPS was $14.13, on revenue of $1.6 billion.
- The Wealth Management segment's revenue for Q4 2025 was $287.3 million, an increase of 13.3% compared to the prior year, resulting in pre-tax income of $98.8 million, an 84.0% increase. Assets Under Management (AUM) reached a record $55.2 billion at December 31, 2025.
- The Capital Markets segment reported revenue of $182.9 million for Q4 2025, a 53.3% increase year-over-year, and achieved pre-tax income of $52.8 million, a significant improvement from a pre-tax loss in the prior year.
- The company returned value to shareholders by declaring a $1.00 per share special dividend payable in January 2026 and repurchasing 46,292 shares during 2025 at an average price of $64.36 per share. A quarterly dividend of $0.18 per share for Q4 2025 was also announced.
8 days ago
Coincheck Group to Acquire 3iQ
OPY
M&A
New Projects/Investments
- Coincheck Group N.V. has signed an agreement to acquire approximately 97% beneficial ownership of 3iQ Corp., a digital asset manager, from its majority shareholder Monex Group, Inc..
- The transaction values 3iQ at USD 111,840,476 and will be settled by issuing 27,149,684 new Coincheck Group ordinary shares at USD 4.00 per share.
- The acquisition is expected to close in the second calendar quarter of 2026 and is anticipated to be accretive to Coincheck Group's earnings.
- This acquisition is a strategic step for Coincheck Group's global expansion in the institutional digital asset space.
Jan 8, 2026, 12:00 PM
Oppenheimer Holdings Inc. Declares Special Cash Dividend
OPY
Dividends
- Oppenheimer Holdings Inc. (OPY) announced that its Board of Directors declared a special cash dividend of $1.00 per share on Class A non-voting and Class B voting common stock.
- The dividend is payable on January 9, 2026, to shareholders of record as of the close of business on December 26, 2025.
- The aggregate payment for this special dividend will be approximately $10.5 million and will be funded through existing cash management activities.
- The company stated the dividend is to recognize the year’s operating results and improved financial position and to reward shareholders.
Dec 12, 2025, 1:13 PM
Oppenheimer Holdings Declares Special Dividend
OPY
Dividends
- Oppenheimer Holdings Inc. (OPY) has declared a special cash dividend of $1.00 per share on its Class A non-voting and Class B voting common stock.
- The dividend is payable on January 9, 2026, to shareholders of record as of the close of business on December 26, 2025.
- The aggregate payment for this special dividend will be approximately $10.5 million.
- The company's President and CEO, Robert S. Lowenthal, stated that the dividend recognizes the year's operating results and improved financial position.
Dec 12, 2025, 1:00 PM
Kraken Secures $1 Billion Funding, Valued at $20 Billion Ahead of 2026 IPO
OPY
New Projects/Investments
Revenue Acceleration/Inflection
CEO Change
- Kraken has raised a total of $1 billion in funding over the past two months, including $800 million from a consortium of institutional investors such as Oppenheimer Alternative Investment Management, and a $200 million strategic investment from Citadel Securities.
- This capital influx has valued Kraken at $20 billion, positioning the company for an anticipated public listing in 2026.
- The company reported $472 million in Q1 2025 revenue, a 19% increase year over year, and exceeded its $1.5 billion 2024 revenue within the first three quarters of 2025, highlighting accelerating growth.
- The funding round coincided with leadership changes, as Arjun Sethi stepped in as co-CEO alongside David Ripley in October 2024.
Nov 18, 2025, 11:50 PM
Oppenheimer Holdings Inc. Reports Q3 2025 Financial Results and Declares Dividend
OPY
Earnings
Dividends
Revenue Acceleration/Inflection
- Oppenheimer Holdings Inc. reported $424.4 million in revenue and $21.7 million in net income for the third quarter of 2025, resulting in basic earnings per share of $2.06.
- The increase in revenue was primarily driven by robust equity underwriting volumes, higher transaction-based commissions, and greater advisory fees due to a rise in billable assets under management.
- As of September 30, 2025, the company reached record highs in stockholders' equity of $920.3 million, book value per share of $87.47, and tangible book value per share of $70.48.
- The Board of Directors announced a quarterly dividend of $0.18 per share, payable on November 28, 2025, to shareholders of record on November 14, 2025.
Nov 3, 2025, 3:16 PM
Oppenheimer Holdings Inc. Reports Third Quarter 2025 Earnings
OPY
Earnings
Dividends
Revenue Acceleration/Inflection
- Oppenheimer Holdings Inc. reported net income of $21.7 million or $2.06 basic earnings per share for the third quarter of 2025, compared with net income of $24.5 million or $2.38 basic earnings per share for the third quarter of 2024.
- Revenue increased by 13.7% to $424.4 million in Q3 2025 from $373.4 million in Q3 2024, primarily driven by robust equity underwriting volumes and increased advisory fees.
- Third quarter 2025 results were significantly impacted by $13.5 million in higher pre-tax compensation expenses, or $0.95 basic earnings per share after tax, attributable to an increase in the OPY Class A share price.
- Assets Under Management (AUM) reached a record high of $55.1 billion at September 30, 2025, and the Board of Directors declared a quarterly dividend of $0.18 per share.
Oct 31, 2025, 12:38 PM
Barinthus Biotherapeutics Announces Merger with Clywedog Therapeutics
OPY
M&A
Revenue Acceleration/Inflection
CEO Change
- Barinthus Biotherapeutics and Clywedog Therapeutics are merging in an all-stock transaction to form Clywedog Therapeutics, Inc., which will trade on Nasdaq under the ticker "CLYD".
- Barinthus shareholders will own approximately 34% of the combined company, with the deal expected to close in the first half of 2026 after stockholder approval.
- The merger combines Barinthus' immunology and inflammation expertise with Clywedog's metabolic disease portfolio, aiming for an estimated cash runway through 2027.
- Despite Barinthus's 236.2% revenue growth over the past three years, the company faces significant profitability challenges with a negative operating margin of -401.8% and net margin of -463.8%, leading to a premarket decline of over 4% in its shares following the announcement.
Sep 30, 2025, 12:19 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more